Patents by Inventor Geoffrey Walter Grigg
Geoffrey Walter Grigg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090325815Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from rearranged V-gene sequences of unimmunised mammal.Type: ApplicationFiled: June 19, 2009Publication date: December 31, 2009Applicants: MEDICAL RESEARCH COUNCIL, CAMBRIDGE ANTIBODY TECHNOLOGY LIMITEDInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 7195866Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: December 19, 2002Date of Patent: March 27, 2007Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Publication number: 20040086944Abstract: A method for detecting presence of a target DNA in a sample, the method comprising: (a) treating a sample containing DNA with an agent that modifies unmethylated cytosine; (b) providing to the treated sample a detector ligand capable of binding to a target region of DNA and allowing sufficient time for a detector ligand to bind to a target DNA; and (c) measuring binding of the detector ligand to DNA in the sample to determine the presence of the target DNA in a sample.Type: ApplicationFiled: October 20, 2003Publication date: May 6, 2004Inventors: Geoffrey Walter Grigg, Peter Molloy, Douglas Spencer Millar
-
Publication number: 20030190674Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: ApplicationFiled: December 19, 2002Publication date: October 9, 2003Applicant: Medical Research CouncilInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6593081Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: March 21, 2000Date of Patent: July 15, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Publication number: 20030118525Abstract: The present invention relates to methods for the treatment or prevention of skin damage and/or UV-induced immuno-suppression. In particular, the invention relates to methods for the treatment or prevention of UV-induced immunosuppression, skin erythenma and skin collagen damage which involve the administration of carnosine, acycarnosine or related compounds.Type: ApplicationFiled: October 29, 2002Publication date: June 26, 2003Inventor: Geoffrey Walter Grigg
-
Patent number: 6582915Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 28, 2000Date of Patent: June 24, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6555313Abstract: Methods are disclosed for the production of human self-antibodies and antibody fragments, which bind human antigens. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Human antibodies or antibody fragments are selected by binding with human antigens. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding to and is a human antigen. Nucleic acid libraries used may be derived from V-gene sequences of unimmunised humans. Part or all of the nucleic acid may be derived from oligonucleotide synthesis.Type: GrantFiled: May 16, 2000Date of Patent: April 29, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6544731Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: April 8, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 6521404Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: November 20, 1998Date of Patent: February 18, 2003Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg
-
Patent number: 5885793Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self-antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface a member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.Type: GrantFiled: October 26, 1994Date of Patent: March 23, 1999Assignees: Medical Research Council, Cambridge Antibody Technology LimitedInventors: Andrew David Griffiths, Hendricus Renerus Jacobus Mattheus Hoogenboom, James David Marks, John McCafferty, Gregory Paul Winter, Geoffrey Walter Grigg